Medasense Biometrics Ltd. announced today that it has received CE mark approval for its novel Pain Monitoring Device, PMD-200™.
This new technology is now available to help physicians objectively assess a patient’s pain in critical care situations, where patients are unable to communicate. This allows physicians to ensure pain is properly managed.
For more information and to access the full PR click here.